LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

Biogen Inc

Gesloten

SectorGezondheidszorg

140.29 0.24

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

140.04

Max

141.94

Belangrijke statistieken

By Trading Economics

Inkomsten

394M

635M

Verkoop

215M

2.6B

K/W

Sectorgemiddelde

12.653

35.733

EPS

3.02

Winstmarge

23.995

Werknemers

7,605

EBITDA

457M

1B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+20.72% upside

Dividenden

By Dow Jones

Volgende Winsten

29 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

442M

19B

Vorige openingsprijs

140.05

Vorige sluitingsprijs

140.29

Nieuwssentiment

By Acuity

31%

69%

92 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Biogen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 sep 2025, 09:30 UTC

Acquisities, Fusies, Overnames

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

6 sep 2025, 08:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

5 sep 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

5 sep 2025, 20:37 UTC

Acquisities, Fusies, Overnames

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5 sep 2025, 20:37 UTC

Acquisities, Fusies, Overnames

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5 sep 2025, 20:36 UTC

Acquisities, Fusies, Overnames

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5 sep 2025, 20:36 UTC

Acquisities, Fusies, Overnames

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5 sep 2025, 20:33 UTC

Acquisities, Fusies, Overnames

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5 sep 2025, 20:33 UTC

Acquisities, Fusies, Overnames

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5 sep 2025, 20:31 UTC

Acquisities, Fusies, Overnames

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5 sep 2025, 20:20 UTC

Winsten

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 sep 2025, 19:23 UTC

Marktinformatie

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5 sep 2025, 19:22 UTC

Winsten

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5 sep 2025, 19:17 UTC

Marktinformatie

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5 sep 2025, 18:59 UTC

Winsten

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 sep 2025, 18:35 UTC

Marktinformatie

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5 sep 2025, 17:25 UTC

Marktinformatie

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5 sep 2025, 17:20 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5 sep 2025, 17:17 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 sep 2025, 17:17 UTC

Marktinformatie

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5 sep 2025, 17:03 UTC

Marktinformatie

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5 sep 2025, 16:39 UTC

Acquisities, Fusies, Overnames

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5 sep 2025, 16:39 UTC

Acquisities, Fusies, Overnames

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5 sep 2025, 16:39 UTC

Acquisities, Fusies, Overnames

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5 sep 2025, 16:39 UTC

Acquisities, Fusies, Overnames

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5 sep 2025, 16:37 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

5 sep 2025, 16:37 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Energy Roundup: Market Talk

5 sep 2025, 16:37 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5 sep 2025, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

5 sep 2025, 16:16 UTC

Winsten

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Biogen Inc Prognose

Koersdoel

By TipRanks

20.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 169.81 USD  20.72%

Hoogste 260 USD

Laagste 118 USD

Gebaseerd op 26 Wall Street-analisten die 12-maands prijsdoelen bieden voor Biogen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

26 ratings

12

Buy

14

Hold

0

Sell

Technische score

By Trading Central

118.15 / 121.17Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

92 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat